Effective Pairing Targets Pseudomonas Aeruginosa
Monash University researchers have discovered a groundbreaking antibiotic combination capable of combating Pseudomonas aeruginosa, a bacterium known for causing severe infections like pneumonia and meningitis. This development is critical because Pseudomonas aeruginosa is identified by the World Health Organisation as a high-priority pathogen due to its resistance to many antibiotics.
Published in The Lancet Microbe, the study reveals that pairing two commonly used b2-lactam antibiotics can effectively target this drug-resistant pathogen. These antibiotics are the most frequently utilised class against serious infections. The research utilised a validated laboratory infection system to simulate antibiotic dosing regimens as they occur in hospital settings.
“The combination regimen results in faster and more substantial bacterial killing than when each antibiotic is used alone,” said Associate Professor Cornelia Landersdorfer from the Monash Institute of Pharmaceutical Sciences. The method demonstrated significant success in suppressing resistance to both antibiotics.
Quantitative Systems Pharmacology Model
The study also developed a quantitative systems pharmacology (QSP) model to predict patient outcomes. This model, incorporating genetic data, aims to optimise antibiotic regimens tailored to individual infections. Such predictive models are essential in the fight against antimicrobial resistance (AMR), which was responsible for 1.14 million deaths in 2021.
Associate Professor Antonio Oliver stated, “Rapid diagnostics could facilitate personalized therapies, catering to specific resistance characteristics of pathogens.” The development of new antibiotics has lagged behind the rapid rise in AMR, jeopardizing modern medical treatments.
The implications of AMR extend beyond individual infections, threatening medical procedures like surgery and chemotherapy. As bacteria develop resistance to several commonly used antibiotics, infections become more challenging to treat, escalating the risk of disease spread and severe illness.
Last updated: 29 June 2026, 11:46 am
